A recent study published in JAMA Network Open suggests that breast cancer survivors who receive chemotherapy may face a more pronounced and long-lasting decline in their physical health compared to those treated only with endocrine therapy. This large-scale prospective cohort investigation sheds light on the differential impact of various treatment regimens, pointing to the need for more informed decision-making when balancing therapeutic benefits against potential long-term side effects.
Study Background
Researchers analyzed a pool of 15,392 women aged 30 to 65, of whom 2,566 had been diagnosed with breast cancer and 12,826 were age-matched controls without any cancer history aside from nonmelanoma skin cancer. Enrollees spanned the years 2006 to 2013, with baseline data collections initiating in 2015. Among the participants with breast cancer, 433 received neither chemotherapy nor endocrine therapy, 1,223 received endocrine therapy alone, 276 received only chemotherapy, and 634 underwent a combined regimen of chemotherapy and endocrine therapy.
The majority of diagnosed patients (82.2%) presented with hormone receptor–positive disease, 54.8% had localized breast cancer, and 23.7% had breast cancer in situ. The median age of both the cancer and non-cancer cohorts was 54.1 years. Most participants were White, with nearly half of the breast cancer cohort identified as postmenopausal at diagnosis. These demographics provided a broad look at the patterns of treatment choices and their potential long-term effects on patient well-being.
Assessment Methods
Investigators administered the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health v1.2 questionnaire at baseline and again in both 2015 and 2018. This survey measured self-reported physical health, fatigue, pain, and day-to-day functional abilities. Raw scores were converted into standardized T-scores following the Global Health scoring manual. A higher T-score indicated poorer outcomes, such as increased fatigue or diminished ability to perform daily tasks.
READ MORE: New Video-Based Method Enhances Detection of Infantile Spasms Syndrome
The study design allowed researchers to examine multiple time intervals following a cancer diagnosis, including the period up to two years post-diagnosis, between two and five years, and beyond five years. By capturing data at these distinct stages, the authors aimed to pinpoint when survivors were most vulnerable to physical health declines and how treatment-related factors contributed to these patterns.
Early Physical Declines (Up to Two Years)
In the early window—defined as the first two years after diagnosis—women who received both chemotherapy and endocrine therapy showed the steepest dip in physical health (β = −3.26; 95% CI, −3.97 to −2.55). This was followed by those who received chemotherapy alone (β = −3.13; 95% CI, −4.19 to −2.07). By contrast, survivors treated only with endocrine therapy saw a more modest reduction in physical health (β = −1.12; 95% CI, −1.64 to −0.60).
Researchers attributed this pronounced effect among chemotherapy recipients to the intensity of systemic treatment, which, while critical for reducing recurrence in certain tumor profiles, can also impose a substantial burden on healthy tissues. The relatively smaller decline in the endocrine-only group suggested that for some women, forgoing chemotherapy—when oncologically appropriate—could yield better physical function in the short term.
Intermediate Outcomes (Two to Five Years)
From two to five years post-diagnosis, the gap persisted among the groups, though the rankings shifted slightly. Recipients of chemotherapy plus endocrine therapy remained most affected (β = −1.34; 95% CI, −2.07 to −0.61). Chemotherapy-only patients followed with a persistent decline (β = −1.20; 95% CI, −2.32 to −0.07). Meanwhile, endocrine-only patients experienced the least pronounced reduction over this period (β = −0.40; 95% CI, −0.94 to 0.14).
Though the difference in scores narrowed compared to the initial period, the data still show an ongoing toll on survivors who underwent chemotherapy. This aligns with established knowledge about the cumulative side effects of cytotoxic drugs, which can manifest in muscle weakness, fatigue, or pain that extends for several years after the last treatment cycle.
Longer-Term Trajectories (Beyond Five Years)
A noteworthy finding emerged once survivors surpassed the five-year mark. Those who had received chemotherapy alone recorded the greatest decline in physical function (β = −4.09; 95% CI, −5.91 to −2.27). Patients in the combined chemotherapy and endocrine therapy group did show lingering effects (β = −1.65; 95% CI, −2.85 to −0.46), but their decline was less dramatic than in the chemo-only cohort. Women who underwent endocrine therapy alone experienced a comparatively negligible change (β = −0.11; 95% CI, −1.07 to 0.85), suggesting that they were better positioned to maintain day-to-day functional capacity as time progressed.
An in-depth look at metrics like fatigue, pain, and basic daily functioning reinforced this picture. Self-reported physical health scores at or beyond the five-year mark were highest (signifying poorer outcomes) among patients treated solely with chemotherapy (β = 2.25; 95% CI, 1.38-3.67). Patients in the combination group had somewhat lower, though still elevated, scores (β = 1.74; 95% CI, 1.25-2.42). The endocrine-only cohort, with a β of 1.02 (95% CI, 0.79-1.33), displayed less severe decrements.
Impact of Aromatase Inhibitors
Within the endocrine-therapy group, the most discernible physical decline was primarily restricted to those on aromatase inhibitors, a key therapy for hormone receptor–positive breast cancer in postmenopausal women. The possibility that this medication class drives a particular subset of survivors to experience stiffness, joint pain, or other limiting side effects highlights the importance of individualized approaches. Identifying which subgroups are more vulnerable allows oncologists to tailor regimens and implement interventions that can mitigate such adverse outcomes.
Expert Perspectives
Dr. Clara Bodelon, the study’s lead author and a senior principal scientist of survivor research at the American Cancer Society, highlighted the positive implications of the research for patients who do not medically require chemotherapy. According to her statement in a press release, if a patient’s clinical profile suggests they can safely forego chemotherapy, their risk of encountering severe or extended physical health declines diminishes significantly. However, Dr. Bodelon emphasized that further research is necessary to confirm these preliminary findings and clarify the spectrum of long-term health consequences across different breast cancer therapies.
In an interview with CancerNetwork, she also underscored the need for each member of a patient’s care team, from oncologists to primary care physicians, to be well-informed about the potential for enduring physical declines. Such awareness can guide more nuanced risk-benefit discussions, encouraging patients to consider not only survival outcomes but also daily quality of life.
Clinical Decision-Making
Chemotherapy remains a cornerstone in many breast cancer treatment plans, especially for aggressive or high-risk cases. Yet, this study indicates that patients with certain tumor subtypes, hormone receptor statuses, or lower relapse risk might forego chemotherapy without significantly compromising survival, thus preserving better long-term physical function. Ultimately, these choices depend on close consultation between the patient and a multidisciplinary medical team.
Additionally, the data underscore the importance of survivorship care that extends well beyond the completion of active treatment. Rehabilitation services such as physical therapy can assist in restoring muscle strength and range of motion, and psychological support or counseling may help survivors cope with fatigue and chronic pain. A well-rounded plan that addresses diet, exercise, and mental health can alleviate the burden of lasting treatment side effects.
Ongoing Research Needs
While these findings add a crucial layer to the understanding of breast cancer survivorship, researchers recognize that more specialized inquiries are warranted. For instance, focusing on pre-existing conditions, racial or ethnic disparities, and different chemotherapy regimens can enhance the precision of clinical recommendations. More refined studies might also investigate whether certain biomarkers predict which patients are likeliest to suffer the greatest physical decline, thus enabling more individualized therapy choices.
Moreover, the study’s authors call attention to the evolving nature of breast cancer treatments, as targeted therapies, immunotherapies, and novel endocrine agents emerge. Future investigations must adapt to these innovations, continually evaluating the interplay between potent anti-cancer benefits and the minimization of long-term harm.
Practical Implications for Survivors
Breast cancer survivors frequently face a complex array of challenges following their initial therapies. These can range from lingering fatigue and pain to psychological stress over possible recurrence. By quantifying the long-term physical repercussions of chemotherapy, this research empowers survivors to advocate for care strategies that acknowledge both oncologic control and overall quality of life.
Healthcare professionals can build on these insights by designing personalized post-treatment programs, such as structured exercise regimes or occupational therapy, to help patients gradually reclaim their former levels of activity. Identifying and addressing problems like depression or anxiety is also crucial, as mental health issues can exacerbate the physical difficulties documented in survivors.
Conclusion
The results from this large cohort study highlight the persistent effects that chemotherapy can have on breast cancer survivors, especially compared to endocrine therapy alone. Although chemotherapy has undoubtedly played a pivotal role in lowering mortality rates, these findings underscore the delicate balance between effective treatment and long-term physical well-being. For many women, choosing a therapy plan may involve weighing both survival benefits and potential impacts on daily functioning for years to come. As personalized medicine advances, patients and clinicians alike stand to benefit from approaches that integrate robust efficacy with a sharper focus on survivorship and quality of life.
